Although small molecules can be excellent at finding and binding deep pockets on proteins of interest, many therapeutic targets with smooth surfaces remain hard to get a good handle on. Partly as a ...

Molly Gibson, PhD, has focused her attention on building companies at the intersection of AI and life sciences for the past decade, having co-founded both Generate: Biomedicines and Lila Sciences.

A structure of the drug ibrutinib. The drug ibrutinib makes a covalent bond to Bruton's tyrosine kinase, an important cancer target. Credit: RCSB PDB/Yang H. Ku Enticing atoms to share their electrons ...

Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...